| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Vincenzo Sforza | Q56953948 |
| Giuseppina Liguori | Q63412293 | ||
| Claudia Cardone | Q87293374 | ||
| P2093 | author name string | Fortunato Ciardiello | |
| Alfonso Reginelli | |||
| Teresa Troiani | |||
| Erika Martinelli | |||
| Giulio Belli | |||
| Stefania Napolitano | |||
| Giulia Martini | |||
| Valentina Gambardella | |||
| Carminia Della Corte | |||
| Marianna L Ferrara | |||
| P2860 | cites work | Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. | Q38934630 |
| Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. | Q38996793 | ||
| Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells | Q39079626 | ||
| Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents | Q39224151 | ||
| Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas | Q39384830 | ||
| MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy | Q39625657 | ||
| Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. | Q39752760 | ||
| Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study | Q39821902 | ||
| PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers | Q39859169 | ||
| Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review | Q24289005 | ||
| Oncogenic ERBB3 mutations in human cancers | Q24293022 | ||
| Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer | Q24563539 | ||
| Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab | Q24600031 | ||
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Q24600932 | ||
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers | Q26781362 | ||
| Prognostic value of c-Met in colorectal cancer: a meta-analysis | Q26860232 | ||
| Tumour heterogeneity and the evolution of polyclonal drug resistance | Q26866803 | ||
| PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis | Q26992267 | ||
| The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations | Q27649316 | ||
| A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies | Q27675148 | ||
| K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions | Q27680654 | ||
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer | Q39887307 | ||
| Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. | Q39899490 | ||
| Randomized trial of TAS-102 for refractory metastatic colorectal cancer | Q41741632 | ||
| Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours | Q42876061 | ||
| PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. | Q43562170 | ||
| A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer | Q44093928 | ||
| Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab | Q45102101 | ||
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. | Q46034442 | ||
| Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer | Q46233566 | ||
| A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study | Q46679647 | ||
| Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO | Q50976831 | ||
| Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. | Q50993154 | ||
| Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. | Q51752412 | ||
| Effects of atropine and glycopyrrolate on cognitive function following anaesthesia and electroconvulsive therapy (ECT). | Q51802723 | ||
| FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. | Q53520406 | ||
| Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. | Q54279287 | ||
| Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. | Q54343844 | ||
| Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study | Q57152185 | ||
| RAF/RAS oncogenes and mismatch-repair status | Q57281056 | ||
| ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making | Q57758061 | ||
| Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors | Q58614658 | ||
| Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice | Q71803596 | ||
| Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer | Q77555522 | ||
| High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice | Q82839912 | ||
| More on influenza vaccine in young children | Q84470306 | ||
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer | Q27851407 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | Q27851465 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab | Q27851587 | ||
| KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. | Q27851616 | ||
| Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer | Q27851708 | ||
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 | ||
| A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
| Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients | Q27853121 | ||
| Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis | Q27853129 | ||
| Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. | Q27853212 | ||
| Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. | Q27853216 | ||
| Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer | Q27853224 | ||
| Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. | Q27853329 | ||
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study | Q28238311 | ||
| Raf kinase as a target for anticancer therapeutics | Q28244900 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| The biology and clinical relevance of the PTEN tumor suppressor pathway | Q28272157 | ||
| Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival | Q28277824 | ||
| KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy | Q28285473 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer | Q28308193 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| ras oncogenes in human cancer: a review | Q29547769 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| The causes and consequences of genetic heterogeneity in cancer evolution | Q29615848 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| PI3K and cancer: lessons, challenges and opportunities | Q30080017 | ||
| A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer | Q33418329 | ||
| Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials | Q34263478 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | Q34624122 | ||
| PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color | Q34660907 | ||
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial | Q34663697 | ||
| Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34664272 | ||
| Drug development of MET inhibitors: targeting oncogene addiction and expedience | Q34782774 | ||
| Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. | Q35102480 | ||
| Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer | Q35212113 | ||
| The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. | Q35584314 | ||
| Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab | Q35705200 | ||
| Mutation of the PIK3CA oncogene in human cancers | Q36383360 | ||
| Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. | Q36471372 | ||
| PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients | Q36611365 | ||
| Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients | Q36755257 | ||
| Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial | Q36977022 | ||
| PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer | Q37137091 | ||
| Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition | Q37331610 | ||
| Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. | Q37593624 | ||
| Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients | Q37636844 | ||
| Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions | Q37826270 | ||
| Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials | Q38239192 | ||
| Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution | Q38257912 | ||
| Recent therapeutic advances in the treatment of colorectal cancer | Q38262231 | ||
| PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab | Q38584695 | ||
| Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. | Q38876494 | ||
| Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic | Q38882465 | ||
| Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations | Q38910529 | ||
| Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. | Q38916276 | ||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 6345-6361 | |
| P577 | publication date | 2016-07-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer | |
| P478 | volume | 22 |
| Q104617809 | An insight into small extracellular vesicles: Their roles in colorectal cancer progression and potential clinical applications |
| Q46744252 | Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. |
| Q38374623 | Current and Emerging Applications of Droplet Digital PCR in Oncology |
| Q43492228 | Current and future biomarkers in colorectal cancer |
| Q33618547 | Diagnostic performance of magnetic resonance imaging and 3D endoanal ultrasound in detection, staging and assessment post treatment, in anal cancer |
| Q91998214 | Diagnostic value/performance of radiological liver imaging during chemoterapy for gastrointestinal malignancy: a critical review |
| Q58695934 | Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer |
| Q91998201 | Internal hernias: a difficult diagnostic challenge. Review of CT signs and clinical findings |
| Q64075971 | KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015 |
| Q91998210 | Magnetic resonance enterography (MRE) and ultrasonography (US) in the study of the small bowel in Crohn's disease: state of the art and review of the literature |
| Q33617869 | Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update. |
| Q39172297 | Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets |
| Q90348651 | Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer |
| Q63499786 | Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series |
| Q91807426 | Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants |
| Q57739115 | Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives |
| Q48192463 | Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity |
| Q55342871 | Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. |
| Q33563293 | Patient considerations in metastatic colorectal cancer - role of panitumumab |
| Q38648300 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets |
| Q90513170 | Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer |
| Q61808208 | Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines |
| Q42366615 | Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. |
| Q91998197 | Relationship between diagnostic imaging features and prognostic outcomes in gastrointestinal stromal tumors (GIST) |
| Q92757568 | Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma |
| Q55088555 | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. |
| Q49379193 | Silencing Lin28 promotes apoptosis in colorectal cancer cells by upregulating let‑7c targeting of antiapoptotic BCL2L1. |
| Q90598608 | The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells |
| Q59807467 | The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status |
| Q42139529 | Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation |
| Q90711354 | Towards the era of precision medicine in metastatic colorectal cancer |
| Q92017307 | Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression |
| Q50659230 | Vascular microinvasion from hepatocellular carcinoma: CT findings and pathologic correlation for the best therapeutic strategies. |
Search more.